Literature DB >> 25256274

Comparison of steroidogenic pathways among normoandrogenic and hyperandrogenic polycystic ovary syndrome patients and normal cycling women.

Sebastião Freitas de Medeiros1, Jacklyne Silva Barbosa, Márcia Marly Winck Yamamoto.   

Abstract

AIM: To compare the corticosteroidogenic enzyme activities between normal cycling non-polycystic ovary syndrome (PCOS), and normoandrogenic PCOS (NA-PCOS) and hyperandrogenic PCOS (HA-PCOS) patients.
METHODS: This cohort study was conducted at Julio Muller University Hospital and Tropical Institute of Reproductive Medicine and Menopause, and enrolled 114 non-PCOS women and 355 PCOS patients. The steroidogenic enzyme activities were measured using the serum steroid product/precursor molar ratio.
RESULTS: In the Δ5 pathway the 17,20 lyase activity was equally low in the NA-PCOS and HA-PCOS women compared with the non-PCOS women (P < 0.01 and P < 0.001, respectively). In the Δ4 pathway, the 17,20 lyase activity was higher only in the HA-PCOS group (P < 0.001). The 17-hydroxylase activity was the same in PCOS and non-PCOS subjects (P > 0.05). The 3β-hydroxysteroid dehydrogenase II (3β-HSDII) activity was higher in the conversion of dehydroepiandrosterone into androstenedione in the HA-PCOS than in the NA-PCOS (P < 0.05) and the non-PCOS patients (P < 0.01). The aromatase activity was lower in the HA-PCOS than in the NA-PCOS (P < 0.05) patients and non-PCOS subjects (P < 0.01). In HA-PCOS subjects, the 17,20 lyase activity was related to insulin, estradiol, total testosterone concentrations and free androgen index in the Δ5 pathway. 3β-HSDII showed weak correlation with estradiol in the HA-PCOS group. Anthropometric parameters had little impact, if any, on the steroidogenic enzyme activities.
CONCLUSION: The NA-PCOS and HA-PCOS patients demonstrated different enzyme activities, and the results provided new directions for future studies including PCOS patients with different phenotypes.
© 2014 The Authors. Journal of Obstetrics and Gynaecology Research © 2014 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  adrenal stimulation; enzyme activity; hyperandrogenism; polycystic ovary syndrome; steroidogenesis

Mesh:

Substances:

Year:  2014        PMID: 25256274     DOI: 10.1111/jog.12524

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  13 in total

Review 1.  Differential activity of the corticosteroidogenic enzymes in normal cycling women and women with polycystic ovary syndrome.

Authors:  Márcia Marly Winck Yamamoto; Sebastião Freitas de Medeiros
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

2.  De Novo and Depot-Specific Androgen Production in Human Adipose Tissue: A Source of Hyperandrogenism in Women with Obesity.

Authors:  Isabel Viola Wagner; Iuliia Savchuk; Lena Sahlin; Alexandra Kulle; Nora Klöting; Arne Dietrich; Paul-Martin Holterhus; Jörg Dötsch; Matthias Blüher; Olle Söder
Journal:  Obes Facts       Date:  2022-01-04       Impact factor: 4.807

3.  Metabolic and endocrine connections of 17-hydroxypregnenolone in polycystic ovary syndrome women.

Authors:  Sebastião Freitas de Medeiros; Cinthia Marenza Ormond; Matheus Antônio Souto de Medeiros; Nayara de Souza Santos; Camila Regis Banhara; Márcia Marly Winck Yamamoto
Journal:  Endocr Connect       Date:  2017-08-07       Impact factor: 3.335

Review 4.  Genetic Variants Associated with Hyperandrogenemia in PCOS Pathophysiology.

Authors:  Roshan Dadachanji; Nuzhat Shaikh; Srabani Mukherjee
Journal:  Genet Res Int       Date:  2018-02-18

Review 5.  Polycystic Ovary Syndrome: Implication for Drug Metabolism on Assisted Reproductive Techniques-A Literature Review.

Authors:  Enrique Reyes-Muñoz; Thozhukat Sathyapalan; Paola Rossetti; Mohsin Shah; Min Long; Massimo Buscema; Gaetano Valenti; Valentina Lucia La Rosa; Stefano Cianci; Salvatore Giovanni Vitale
Journal:  Adv Ther       Date:  2018-10-11       Impact factor: 3.845

Review 6.  Identifying genes associated with the development of human polycystic ovary syndrome.

Authors:  Salina Y Saddick
Journal:  Saudi J Biol Sci       Date:  2020-01-16       Impact factor: 4.219

7.  Reliability of a dried urine test for comprehensive assessment of urine hormones and metabolites.

Authors:  Mark Newman; Desmond A Curran
Journal:  BMC Chem       Date:  2021-03-15

8.  Maternal polycystic ovary syndrome and the risk of autism spectrum disorders in the offspring: a population-based nationwide study in Sweden.

Authors:  K Kosidou; C Dalman; L Widman; S Arver; B K Lee; C Magnusson; R M Gardner
Journal:  Mol Psychiatry       Date:  2015-12-08       Impact factor: 15.992

Review 9.  Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome.

Authors:  Sebastião Freitas de Medeiros
Journal:  Reprod Biol Endocrinol       Date:  2017-12-08       Impact factor: 5.211

10.  The Role of C-Peptide as Marker of Cardiometabolic Risk in Women With Polycystic Ovary Syndrome: A Controlled Study.

Authors:  Sebastiao Freitas de Medeiros; Laura Camila Antunes Angelo; Matheus Antonio Souto de Medeiros; Camila Regis Banhara; Bruna Barcelo Barbosa; Marcia Marly Winck Yamamoto
Journal:  J Clin Med Res       Date:  2018-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.